Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

3 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
7(87.5%)
Phase 2
1(12.5%)
8Total
Phase 1(7)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT05112159Phase 1Completed

Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants

Role: lead

NCT07535489Phase 2Not Yet Recruiting

Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)

Role: lead

NCT06255834Phase 1Completed

Phase 1 Study for IPG11406 in Health Volunteer

Role: lead

NCT07508761Phase 1Not Yet Recruiting

IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors

Role: lead

NCT06717815Phase 1Recruiting

Phase IIa Study for IPG11406 in Patients With Lupus Nephritis

Role: lead

NCT05288543Phase 1Terminated

A Study of Orally Administered IPG7236 in Healthy Adult Participants

Role: lead

NCT05142592Phase 1Recruiting

Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

Role: lead

NCT06212076Phase 1Recruiting

Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients

Role: lead

All 8 trials loaded